Fourteen children with asthma received pemirolast potassium, 0.4mg/kg/day, given two divided doses, for at least 2 weeks. Plasma levels of pemirolast potassium were determined and, symptoms and concomitant medications were scored.
Within 5 hours after drug administration, the plasma levels of pemirolast potassium in all patients were above the effective plasma level of drug, 0.266ug/ml, and they had no asthma symptoms. Between 5 and 10 hours after drug administration, the children, whose plasma levels of drug fell below 0.266pg/ml, became symptomatic. In 6 patients who received the same doses of pemirolast potassium for 6 months, wide individual variations were observed in the drug's half life and nadir plasma levels. Total scores of symptom scores and concomitant medication scores were decreased in patients whose nadir plasma concentrations of pemirolast potassium were above 0.16pg/ml and were not decreased in patients with low nadir plasma level of pemirolast potassium during treatment with pemirolast potassium.
To establish the optimal dose, the pharmacokinetics of pemirolast potassium need to be evaluated in asthmatic children. Large doses may be required to achieve nadir plasma levels neaby 0.266ug/ml in children who exhibit low plasma levels of pemirolast potassium. 
INTRODUCTION

MATERIALS AND METHODS
Study Population
Study participants were 14 Japanese patients (10 boys and 4 girls; mean age, 11.8 years; range, 5 years to 19 years) with chronic asthma who had been seen at the Department of Pediatrics at Hiroshima University School of Medicine between March 1 and December 31, 1994. Each had experienced recurrent episodes of asthma for more than 1 year. Each had a baseline FEVI between 50 and 80% of predicted when not taking antiasthma medications, with an improvement of at least 10% within 30 min after an inhalation of a 3-agonist bronchodilator. Subjects required the daily administration of xanthines,
1-agonists
and inhaled disodium cromoglycate. Patients were excluded from study if they required medications for asthma control containing any oral nonbronchodilator antiallergy drug other than pemirolast.
Informed consent was obtained from the parent of each patient.
Study Design
Pemirolast potassium granules were administered at a dose of 0.4mg/kg/day given in two divided doses at least 2 weeks in addition to the patients' usual regimen of long -acting theophylline (10-22mg/kg/day), Q-agonists, and inhaled disodium cromoglycate. Patients were only permitted to use an inhaled 3-agonist as needed for the relief of asthma symptoms. The dose of drugs except for pemirolast potassium was systemically reduced in the patients whose asthmatic conditions were improved after administration of pemirolast potassium. Plasma concentration of pemirolast potassium in human was reported to be stable on the second day of its ingestion 6). At least three days after the first dose of pemirolast potassium, blood samples were drawn from each subject. Blood samples were collected in EDTA tubes and immediately centrifuged; plasma was removed and Patients with low nadir plasma levels of pemirolast potassium developed asthma attacks more frequently and were in need of concomitant medications more continuously than those whose nadir plasma drug levels were nearby 0.266ug/ml. Although the relation between total scores and plasma levels of pemirolast potassium in our patients could not be examined statistically because of small number of patients in whom clinical data was obtained, we found the tendency that low plasma levels of pemirolast potassium might be cause of frequent asthmatic attacks in this study. The total score of symptom score and concomitant medication score in the patients with low nadir plasma levels of pemirolast potassium may be reduced if the dose of pemirolast potassium is high enough to maintain the lowest plasma level nearby 0.266ug/ml.
We conclude that individualized dosage of pemirolast potassium may be achieved for the good control of asthma symptoms in children.
